Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Gel Approved for Clinical Study in Mild-to-Moderate Atopic Dermatitis
Published Time:
2023-03-21 17:39
Source:
Recently, the second-generation selective JAK1 inhibitor VC005 Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received approval from the NMPAto conduct clinical trials. The target indication is mild-to-moderate atopic dermatitis (AD). Related Phase I clinical trial work is scheduled to commence shortly.
This approval of the topical formulation VC005 marks another significant milestone in the development of VC005, following the approval of the oral tablet formulation for indications including inflammatory bowel disease (IBD), moderate-to-severe atopic dermatitis, ankylosing spondylitis (AS), and rheumatoid arthritis (RA). Currently, multiple Phase II clinical studies for the VC005 tablet have already been initiated.
About VC005
VC005 is a novel, highly potent, and selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug reduces inflammatory responses and immune cell activation, thereby achieving therapeutic effects in inflammatory and autoimmune diseases. Compared to Upadacitinib(a currently marketed JAK inhibitor), VC005 exhibits lower JAK2 inhibitory activity(based on in vitro kinase assays), which may mitigate safety concerns associated with excessive JAK2 inhibition. The drug is currently being developed in two formulations: oral tablets and topical gel.
About JAK1
The JAK/STAT signaling pathway, mediated by JAK family kinases and downstream STAT transcription factors, plays a critical regulatory role in inflammatory and autoimmune diseases such as AS and AD. Current first-generation pan-JAK inhibitors non-selectively inhibit multiple JAK subtypes (e.g., JAK1, JAK2, TYK2) at similar potency levels. Excessive JAK2 inhibition is associated with severe adverse events, prompting the U.S. FDA to issue black box warnings for these agents. Consequently, second-generation selective JAK1 inhibitors like VC005, designed for enhanced safety and efficacy, represent a necessary evolution in therapy.
About AD
AD is a chronic, recurrent, inflammatory skin disease characterized by dry skin, intense pruritus, and eczematous lesions, significantly impairing patients’ quality of life. Epidemiological data indicate that AD affects up to 230 million individuals globally, including 70 million in China, with two-thirds classified as mild and one-third as moderate-to-severe. Prevalence continues to rise globally.
Traditional therapies such as glucocorticoids are limited by adverse effects and poor long-term outcomes, while treatment options for moderate-to-severe patients remain insufficient, leaving many without stable disease control. VC005’s development holds promise for bridging this gap.
Next Page
Related News
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
View Details
29
2026
/
06
On June 26, the authoritative ranking of the "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" (Seed 100 List) was officially released. Relying on its technological moat built by AI-driven original innovation, a complete independent R&D system, a tiered global innovation pipeline, marketed innovative drug achievements and comprehensive global patent portfolio layout, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) has once again been listed in Tier 1 of the ranking, marking its sixth consecutive year on the Seed 100 List.
View Details
26
2026
/
06
Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA. The drug has now entered the NDA stage. As a global pioneer in novel antiplatelet agents, Sumecigrel is expected to provide a new and improved treatment option to tens of millions of patients with cardiovascular and cerebrovascular diseases.
View Details
11
2026
/
06
Recently, VC005 topical gel, a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), has officially obtained the IND approval from the CDE for the topical treatment of plaque psoriasis.
View Details
09
2026
/
06
9 June 2026 – Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech，Company), a commercial-stage innovative biopharmaceutical firm leveraging AI for differentiated original drug design, today announced the signing of an exclusive licensing agreement with Everest Medicines (HKEX: 1952.HK). Under the deal, Vcare PharmaTech grants Everest Medicines exclusive rights for the clinical development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across multiple Asia-Pacific countries and regions (including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR and Taiwan region of China).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn